WO2016080540A1 - Dna-ペプチド併用ワクチン - Google Patents
Dna-ペプチド併用ワクチン Download PDFInfo
- Publication number
- WO2016080540A1 WO2016080540A1 PCT/JP2015/082778 JP2015082778W WO2016080540A1 WO 2016080540 A1 WO2016080540 A1 WO 2016080540A1 JP 2015082778 W JP2015082778 W JP 2015082778W WO 2016080540 A1 WO2016080540 A1 WO 2016080540A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigenic peptide
- peptide
- expression vector
- hepatitis
- virus core
- Prior art date
Links
- 229940001442 combination vaccine Drugs 0.000 title description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 453
- 230000000890 antigenic effect Effects 0.000 claims abstract description 219
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 120
- 229920001184 polypeptide Polymers 0.000 claims abstract description 110
- 239000013604 expression vector Substances 0.000 claims abstract description 100
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 88
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 85
- 230000028993 immune response Effects 0.000 claims abstract description 48
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 32
- 230000001939 inductive effect Effects 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims description 116
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 57
- 229950006323 angiotensin ii Drugs 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 54
- 230000036961 partial effect Effects 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- 206010019280 Heart failures Diseases 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 238000004520 electroporation Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 230000005713 exacerbation Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010027727 Mitral valve incompetence Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- 150000001413 amino acids Chemical group 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 64
- 102400000345 Angiotensin-2 Human genes 0.000 description 53
- 229960005486 vaccine Drugs 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 41
- 230000000694 effects Effects 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 33
- 241000282472 Canis lupus familiaris Species 0.000 description 22
- 125000006850 spacer group Chemical group 0.000 description 22
- 239000007771 core particle Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 241000700159 Rattus Species 0.000 description 18
- 239000008280 blood Substances 0.000 description 17
- 238000001338 self-assembly Methods 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000036772 blood pressure Effects 0.000 description 15
- 241000124008 Mammalia Species 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 108010041986 DNA Vaccines Proteins 0.000 description 10
- 229940021995 DNA vaccine Drugs 0.000 description 10
- 241000282326 Felis catus Species 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002502 liposome Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 7
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000016784 immunoglobulin production Effects 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 6
- 108010012927 Apoprotein(a) Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 108010048036 Angiopoietin-2 Proteins 0.000 description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 description 5
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 229940023041 peptide vaccine Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102400000344 Angiotensin-1 Human genes 0.000 description 4
- 101800000734 Angiotensin-1 Proteins 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000711408 Murine respirovirus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 4
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- -1 sorbit Chemical compound 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- GHKMRHRXQRFQCY-UHFFFAOYSA-N 2,2-dihydroxyethylazanium;bromide Chemical compound [Br-].[NH3+]CC(O)O GHKMRHRXQRFQCY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- VOTJUWBJENROFB-UHFFFAOYSA-N 1-[3-[[3-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VOTJUWBJENROFB-UHFFFAOYSA-N 0.000 description 1
- UPNUQQDXHCUWSG-UHFFFAOYSA-N 1-[6-(4-azido-2-nitroanilino)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O UPNUQQDXHCUWSG-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QLHLYJHNOCILIT-UHFFFAOYSA-N 4-o-(2,5-dioxopyrrolidin-1-yl) 1-o-[2-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethyl] butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)CCC1=O QLHLYJHNOCILIT-UHFFFAOYSA-N 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010264 Condition aggravated Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100332181 Mus musculus Dpp4 gene Proteins 0.000 description 1
- 101000998145 Mus musculus Interleukin-17A Proteins 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 101150076840 PolI gene Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XPKIVYVYXKPGBP-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) decanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCCCC(=O)ON1C(=O)CCC1=O XPKIVYVYXKPGBP-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- IYBKWXQWKPSYDT-UHFFFAOYSA-L ethylene glycol disuccinate bis(sulfo-N-succinimidyl) ester sodium salt Chemical compound [Na+].[Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)C(S([O-])(=O)=O)CC1=O IYBKWXQWKPSYDT-UHFFFAOYSA-L 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 102000047825 human ANGPT2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004969 ion scattering spectroscopy Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a preparation for inducing a specific immune response against an antigenic peptide.
- Vaccine therapy has been proposed in which an immune response to a self-antigen in vivo is positively induced and the activity of the self-antigen is neutralized to prevent or treat a disease contributed by the self-antigen.
- a chimeric hepatitis B virus core antigen polymorphism in which a specific epitope of VEGF and / or a specific epitope of angiopoietin-2 is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. It has been found that administration of an expression vector encoding a peptide can effectively suppress tumor angiogenesis and treat or prevent cancer (Patent Document 3, Non-Patent Document 3).
- electroporation and nucleic acid introduction reagents may be used in combination to increase the introduction efficiency, but these treatments require special administration instruments, devices, reagents, etc., which increases the cost of treatment. There may be an economic burden on the patient.
- treatment such as electroporation and repeated administration of vaccines many times involve physical burdens on the administration subject. Therefore, it is desired to develop a technology that reduces these economic and physical burdens.
- an object of the present invention is to provide a DNA vaccine technique capable of effectively inducing a specific immune response against an antigen without requiring treatment such as electroporation or a nucleic acid introduction reagent.
- the present inventors have found that when the antigenic peptide itself is administered simultaneously with an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide into which the antigenic peptide has been inserted, the specificity to the antigenic peptide is determined.
- specific antibodies are strongly induced.
- a specific antibody against the antigenic peptide could be strongly induced without requiring electroporation or a nucleic acid introduction reagent.
- the simultaneous use of the DNA vaccine and the peptide vaccine continued to increase the antibody titer of the specific antibody against the antigenic peptide for a long period of time compared to the single administration.
- IgG was preferentially induced over IgM by the simultaneous use of DNA vaccine and peptide vaccine. Based on these findings, further studies were made and the present invention was completed.
- the present invention relates to the following.
- [7] The preparation according to any one of [1] to [6], wherein no electroporation and / or nucleic acid introduction reagent is used for administration.
- [8] The preparation according to any one of [1] to [7], which does not contain an adjuvant.
- the self-antigen protein is an antigen that contributes to disease progression.
- the preparation according to [10], wherein the disease is a lifestyle-related disease.
- [13] The preparation according to [12], which is used for treatment or prevention of heart failure, hypertension, renal failure, arteriosclerosis, myocardial infarction, cerebral infarction, obstructive arteriosclerosis, or dementia.
- the preparation according to [15] which is used for treatment or prevention of cancer, diabetic retinopathy, age-related macular degeneration, or retinopathy of prematurity.
- [18] The preparation according to any one of [1] to [16], wherein the application target is a non-human mammal.
- Administering substantially simultaneously the expression vector inserted in the region of ⁇ 87 or 130-138, or added to the N-terminus or C-terminus of the hepatitis B virus core antigen polypeptide Method.
- a combination for use in inducing a specific immune response against an antigenic peptide comprising: (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide into which the antigenic peptide has been inserted or added, wherein the antigenic peptide is amino acid residue 74 of hepatitis B virus core antigen polypeptide
- An expression vector inserted in the region of ⁇ 87 or 130-138, or added to the N-terminus or C-terminus of the hepatitis B virus core antigen polypeptide A combination in which the antigenic peptide of (I) and the expression vector of (II) are administered to an application subject substantially simultaneously.
- [21] Use of a combination in the manufacture of a medicament for inducing a specific immune response against an antigenic peptide, the combination comprising: (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide into which the antigenic peptide has been inserted or added, wherein the antigenic peptide is amino acid residue 74 of hepatitis B virus core antigen polypeptide An expression vector inserted in the region of ⁇ 87 or 130-138, or added to the N-terminus or C-terminus of the hepatitis B virus core antigen polypeptide, Use, wherein the antigenic peptide of (I) and the expression vector of (II) are administered to an application subject substantially simultaneously.
- a vaccine capable of strongly inducing a specific antibody against an antigenic peptide.
- a specific antibody against an antigenic peptide can be effectively induced using a DNA vaccine without requiring treatment such as electroporation or a nucleic acid introduction reagent.
- the increase in the antibody titer of the specific antibody against the antigenic peptide persists for a long period of time, so that the number of vaccine administrations can be reduced.
- the increase of the antibody titer with respect to angiotensin II by DNA + peptide combination vaccine administration is shown.
- the maintenance of the antibody titer against angiotensin II increased by administration of a DNA + peptide combination vaccine for a long period of time is shown.
- the booster effect by the booster to a peptide single administration group (No. 4) and a DNA + peptide combination vaccine administration group (No. 5, 6) is shown.
- the time-dependent change of the antibody titer with respect to angiotensin II after the booster to the peptide single administration group (No. IV4) and the DNA + peptide combination vaccine administration group (No. IV5, IV6) is shown.
- the comparison of the immunity induction effect of a peptide vaccine and a DNA + peptide combination vaccine in a single administration condition is shown.
- the enhancement of immune response by administration of DNA + peptide combination vaccine is shown. It shows the increase in antibody titer by DNA + peptide combination vaccine administration (2W and 4W).
- the vertical axis represents absorbance in ELISA, and the horizontal axis represents serum dilution.
- the increase in antibody titer by administration of DNA + peptide combination vaccine is shown (8W and 12W).
- the vertical axis represents absorbance in ELISA, and the horizontal axis represents serum dilution. It shows an increase in antibody titer by administration of DNA + peptide combination vaccine (2W).
- the test schedule of Example 8 is shown typically. Changes in systolic blood pressure and heart rate of No. 1 individual are shown. The changes in systolic blood pressure and heart rate of No. 2 individuals are shown. The transition of systolic blood pressure and heart rate of the No. 3 individual is shown. The increase of antibody titer by DNA + peptide combination vaccine administration is shown (2W and 5W). Plasma diluted 250-fold was used.
- the vertical axis shows the absorbance in ELISA.
- the present invention is a combination preparation for inducing a specific immune response against an antigenic peptide comprising: (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide into which the antigenic peptide has been inserted or added, wherein the antigenic peptide is amino acid residue 74 of hepatitis B virus core antigen polypeptide
- the present invention provides a preparation comprising an expression vector inserted in the region of ⁇ 87 or 130-138, or added to the N-terminus or C-terminus of the hepatitis B virus core antigen polypeptide.
- An antigenic peptide is recognized by the immune system to be administered and has a specific immune response to the peptide, preferably a specific humoral immune response to the peptide (that is, production of an antibody that specifically recognizes the peptide) refers to a peptide having an activity of inducing.
- Specific recognition of antigen X by an antibody means that the binding affinity of the antibody to antigen X in the antigen-antibody reaction is higher than the binding affinity of non-specific antigen (eg, BSA). .
- the type of the antigenic peptide used in the present invention is not particularly limited as long as it has antigenicity, but is preferably an autoantigen protein or a partial peptide to which the preparation of the present invention is applied.
- An expression vector inserted between groups 80 and 81 is used.
- HBc antigen proteins self-assemble to form spherical core particles. This core particle is very immunogenic.
- this HBc antigen protein can be used as a vaccine platform to induce antibody production against self-antigen proteins and their partial peptides that are not easily recognized by the immune system (D. C. Witacre et al., Expert Rev. Vaccines, vol.8, no.11, pp.1565-1573, 2009; B. E. Clarke et al., Nature, vol.330, pp.381-384, 1987; Japanese Patent No. 3228737).
- the self-antigen protein means an antigen protein encoded on the gene of the animal itself to which the preparation of the present invention is applied.
- the application target of the preparation of the present invention is a mammal.
- mammals include rodents such as mice, rats, hamsters, and guinea pigs, rabbit eyes such as rabbits, ungulates such as pigs, cows, goats, horses, and sheep, cats such as dogs and cats, and humans Primates such as monkeys, rhesus monkeys, cynomolgus monkeys, marmosets, orangutans and chimpanzees.
- the mammal is preferably a feline (dog, cat etc.) or a primate (human etc.).
- the preparation of the present invention when the preparation of the present invention is applied to humans, the use of a human autoantigen protein or a partial peptide thereof is preferably intended, but not limited thereto.
- the preparation of the present invention when the preparation of the present invention is applied to dogs, it is preferably intended to use canine autoantigen protein or a partial peptide thereof, but is not limited thereto.
- the preparation of the present invention when the preparation of the present invention is applied to a cat, the use of a cat autoantigen protein or a partial peptide thereof is preferably intended, but not limited thereto.
- factor X derived from organism Y or “organism Y factor X” means that the amino acid sequence or nucleic acid sequence of factor X in organism Y It means having the same amino acid sequence or nucleic acid sequence as that of Factor X that is naturally expressed.
- the kind of self-antigen protein is not particularly limited, in one aspect, it is an antigen that contributes to disease progression.
- a specific immune response against the autoantigen protein or a partial peptide thereof preferably a specific humoral immune response against the peptide (ie, specifically recognizing the peptide) Production of the antibody to be induced) and the activity of the self-antigen protein is neutralized by the antibody, whereby a disease associated with the exacerbation of the self-antigen protein can be prevented or treated.
- the self-antigen protein is an antigen that contributes to exacerbation of lifestyle-related diseases (lifestyle-related disease-related factors).
- lifestyle-related diseases are a general term for diseases caused by lifestyle habits such as eating habits, exercise habits, rest, smoking, and drinking. Lifestyle-related diseases include hypertension, hyperlipidemia, diabetes, insulin resistance, arteriosclerosis (obstructive arteriosclerosis, etc.), ischemic disease (myocardial infarction, stroke, etc.), obesity, diabetic retinopathy, Examples include hyper-LDL blood.
- the antibody production against the lifestyle-related disease-related factor is induced, and the antibody neutralizes the lifestyle-related disease related factor.
- the autoantigen protein is a humoral factor.
- a humoral factor protein instead of an intracellular protein or cell surface protein as a self-antigen protein, humoral immunity to the humoral factor is predominantly induced, and induced immunity (cellular immunity and humoral humorality).
- the activity of the humoral factor can be effectively neutralized while avoiding adverse effects on normal tissues due to immunity, particularly cellular immunity.
- VEGF vascular endothelial growth factor
- ACE renin
- CETP cholesteryl ester transfer protein
- angiopoietin-2 VEGF-A, B, C, D or E
- PLGF-1, or PLGF-2 VEGF-1, or PLGF-2
- angiopoietin-2 VEGF-1, or PLGF-2
- apolipoprotein a
- PCSK9 proprotein convertase subtilisin / kexin type 9
- DPP4 Dipeptidyl Peptidase-4
- IL-17 interleukin 17
- Angiotensin II, angiotensin I, ACE and renin contribute to exacerbation of heart failure, hypertension, hyperlipidemia and renal failure.
- CETP contributes to exacerbation of hyperlipidemia.
- VEGF and angiopoietin-2 promote tumor angiogenesis and contribute to the exacerbation of cancer (particularly solid cancer).
- Apolipoprotein (a) contributes to exacerbation of arteriosclerosis (particularly atherosclerosis).
- PCSK9 is involved in hyper LDLemia.
- DPP4 is involved in diabetes and insulin resistance.
- IL-17 is involved in autoimmune and inflammatory diseases such as rheumatism, SLE and ulcerative colitis, and cancer.
- the size of the antigenic peptide used in the present invention is usually 5 to 30 amino acids, preferably 6 to 25 amino acids, more preferably 10 to 18 amino acids, and even more preferably 11 to 16 amino acids. If the peptide is too small, antigenicity may be lost. Also, if the peptide is too long, the chimeric hepatitis B virus core antigen polypeptide is difficult to form a core particle by self-assembly, and as a result, production of an antibody that specifically recognizes the peptide may not be effectively induced. is there.
- the partial peptide when used as the antigenic peptide, is preferably specific for the autoantigen protein. “Specific” means that the gene product other than the self-antigen protein naturally expressed in the mammal from which the self-antigen protein is derived (excluding the variable region of immunoglobulin and T cell receptor) is the part. It means not containing a peptide.
- the partial peptide used is that when an antibody that recognizes the partial peptide is bound to the partial peptide in the self-antigen protein, Those at positions where the activity of the self-antigen protein is inhibited are preferably selected.
- Such partial peptides can be at functional sites such as, for example, receptor binding sites, divalent ion binding sites, sites recognized by specific enzymes.
- a partial peptide contained in a site that is removed during the maturation process of a protein such as a signal sequence is preferably excluded from the partial peptide used in the present invention.
- a person skilled in the art can select an appropriate partial peptide based on the three-dimensional structure of the self-antigen protein.
- partial peptide of a self-antigen protein when used as an antigenic peptide, specific examples of the partial peptide include the following.
- VEGF vascular endothelial growth factor
- IMRIKPHQSQHIG SEQ ID NO: 1
- MRIKPHQ SEQ ID NO: 2
- MQIMRIKPHQSQHIGEM SEQ ID NO: 3
- IMRIKPHQGQHIG SEQ ID NO: 4
- MRIKPHQ SEQ ID NO: 5
- MQIMRIKPHQGQHIGEM SEQ ID NO: 6
- SEQ ID NOs: 1, 2, and 3 are partial amino acid sequences of mouse VEGF-A.
- SEQ ID NOs: 4, 5 and 6 are partial amino acid sequences of human VEGF-A.
- the length of the partial sequence is 8, 9, 10, 11, 12, 13, 14, 15 or 16 amino acids.
- SEQ ID Nos: 7 and 8 are partial amino acid sequences of human angiopoietin-2.
- m) is a full-length peptide of angiotensin II.
- DRVYIHPF SEQ ID NO: 21
- an antibody having a higher specificity for angiotensin II than for angiotensin I is induced. Since the amino acid sequence of angiotensin II is common in humans, dogs, cats, mice, and rats, the peptides a) to m) are not only used for humans but also for dogs, cats, mice, and rats. Is also applicable.
- RDGFLLLQMDFGFPEHLLVDFLQSL (SEQ ID NO: 22) a) is a partial peptide of human, mouse and rabbit CETP.
- SEQ ID NO: 23 is a partial amino acid sequence of human apolipoprotein (a).
- DPP4 Proc Natl Acad Sci U S A. 2014 Apr 1; 111 (13): E1256-63) a) SKDEAAADSRRT (SEQ ID NO: 33) b) KSTFRVKSYS (SEQ ID NO: 34) c) ENSTFESFG (SEQ ID NO: 35) a) to c) are partial peptides of mouse DPP4 (a: 29-40aa, b: 48-57aa, c: 89-97aa).
- IL-17 (Immunotherapy, vol. 4, no. 12, 1799-1807, 2012) a) SSACPNTEAKD (SEQ ID NO: 36) b) KVSSRRPSDYLNRSTS (SEQ ID NO: 37) c) HRNEDPDRYPSVIWE (SEQ ID NO: 38) d) KREPESCPFT (SEQ ID NO: 39) e) EKMLVGVGCTCVASI (SEQ ID NO: 40) a) to e) are partial peptides of mouse IL-17.
- a partial peptide of a human orthologue protein corresponding to the above partial peptide of a non-human mammal protein may also be useful as an antigenic peptide.
- Such an antigenic peptide is obtained by aligning the amino acid sequence of a protein of a non-human mammal and the amino acid sequence of a human ortholog protein and identifying a region in the amino acid sequence of the human ortholog protein corresponding to the partial peptide of interest. Those skilled in the art can easily identify them.
- the antigenic peptide (I) is preferably isolated. “Isolated” means that an operation to remove factors other than the target cells and components has been performed, and the state existing in nature has been removed.
- the purity of “isolated antigenic peptide X” is usually 70% or more, preferably 80% or more, more preferably 90% or more. More preferably, it is 99% or more, and most preferably 100%.
- the antigenic peptide (I) is a complex cross-linked to a carrier protein such as bovine serum albumin, KLH (KeyholeKeyLimpet Hemocyanin), VLP (Virus like particle), etc. in order to facilitate recognition by the immune system. As such, it may be contained in the preparation of the present invention. In this case, the purity of the “isolated antigenic peptide X” is calculated by replacing the purity of the isolated complex.
- a carrier protein such as bovine serum albumin, KLH (KeyholeKeyLimpet Hemocyanin), VLP (Virus like particle), etc.
- the method for crosslinking the antigenic peptide to the carrier protein is not particularly limited, and can be performed using a known protein crosslinking agent.
- protein crosslinking agents include aldehydes (eg, glutaraldehyde, paraformaldehyde, formaldehyde, etc.), heterobivalent reactive crosslinkers (ANB-NOS, BMPS, EMCS, GMBS, LC-SPDP, MBS, PDPH, SBA, SIA, SMCC, SMPB, SMPH, SPDP, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-SANPAH, Sulfo-SMCC, etc.), homobivalent reactive crosslinkers (BS2G, BS3, DSG, DSPS, DSSeb, DST, DTSSP, EGS, Sulfo-EGS, etc.) Zero-spacer crosslinkers (CDI, DCC, EDC-HCL, NHS, Sulfo-NHS
- a sulfhydryl group may be introduced by adding cysteine to the end of the antigenic peptide in order to facilitate crosslinking.
- a spacer sequence may be introduced at the end of the antigenic peptide in order to stably present the antigenic peptide on the complex while maintaining its structure and to facilitate the access of the antibody to the antigenic peptide.
- the length of the spacer sequence is not particularly limited as long as the antigenicity of the antigenic peptide is not lost, but it is usually 1 to 10 amino acids, preferably 1 to 5 amino acids, more preferably 1 to 3 amino acids.
- the antigenic peptide and carrier protein are immobilized with an aldehyde (such as glutaraldehyde) without adding a spacer sequence to the end of the antigenic peptide.
- an aldehyde such as glutaraldehyde
- the hepatitis B virus core antigen polypeptide used in the present invention is: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 24, or (2) 90% or more (preferably 95% or more, more preferably 97% or more, still more preferably) with the amino acid sequence represented by SEQ ID NO: 24 Is a polypeptide having an amino acid sequence having an identity of 99% or more) and having an activity of forming a core particle by self-assembly.
- Self-assembly refers to a phenomenon in which an aggregate is formed by the association of molecules dissolved in a solution.
- a core particle refers to a rigid structure having an inherent repetitive configuration.
- the core particle herein may be a product of a synthesis process or a product of a biological process.
- polypeptide of the aspect (2) examples include a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 25 disclosed in WO2003 / 031466.
- One or more cysteine residues at positions corresponding to positions 48, 61, 107 and 185 of the polypeptide having the amino acid sequence represented by SEQ ID NO: 25 have been deleted or other amino acid residues (e.g. A polypeptide substituted with a serine residue) is also preferable as the polypeptide of the embodiment (2).
- a cysteine residue at a similar position in a polypeptide having an amino acid sequence different from that shown in SEQ ID NO: 25 is also deleted or substituted with another amino acid residue.
- Polypeptides obtained by these deletions and substitutions are also included in the polypeptide of the embodiment (2).
- polypeptide of the embodiment of (2) includes a mutant polypeptide in which the isoleucine residue at the position corresponding to position 97 in SEQ ID NO: 25 is substituted with a leucine residue or a phenylalanine residue (Yuan Et al., J. Virol. 73, 10122-10128 (1999)).
- the variants are positions 12, 13, 21, 22, 24, 29, 32, 33, 35, 38, 40, 42, 44, 45, 49, 51, 57, 58, 59, 64, SEQ ID NO: 25, 66, 67, 69, 74, 77, 80, 81, 87, 92, 93, 97, 98, 100, 103, 105, 106, 109, 113, 116, 121, 126, 130, 133, 135, 141,
- the amino acid sequences at many positions are different, including amino acid residues corresponding to the amino acid residues present at 147, 149, 157, 176, 178, 182 and 183.
- polypeptide comprising the amino acid sequence of the HBcAg variant described in WO 01/98333, WO 01/77158 and WO 02/14478, all of which are incorporated herein by reference. And (2) the polypeptide of the embodiment.
- the position of the amino acid residue of the amino acid sequence of the hepatitis B virus core antigen polypeptide is specified based on the amino acid sequence represented by SEQ ID NO: 24 unless otherwise specified.
- the amino acid sequence of the polypeptide is aligned with the amino acid sequence represented by SEQ ID NO: 24, and the position of the corresponding amino acid residue is adopted. .
- the hepatitis B virus core antigen polypeptide used in the present invention is preferably a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 24.
- the antigenic peptide is amino acid residues 74 to 87 or 130 of the hepatitis B virus core antigen polypeptide. Inserted in the region of ⁇ 138, or added to the N-terminus or C-terminus of the hepatitis B virus core antigen polypeptide. Since the region of amino acid residues 74 to 87 and 130 to 138 of the hepatitis B virus core antigen polypeptide is a B cell epitope of the hepatitis B virus core antigen polypeptide (Pumpens et al.
- the antigenic peptide is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
- the antigenic peptide is inserted into the amino acid residue 74 to 87 or 130 to 138 region of the hepatitis B virus core antigen polypeptide.
- the obtained chimeric hepatitis B virus core antigen polypeptide comprises the following components (a) to (c): (A) N-terminal partial polypeptide residue of hepatitis B virus core antigen polypeptide (consisting of a continuous partial amino acid sequence from the N-terminus of hepatitis B virus core antigen polypeptide to amino acid residue X) (where, X is any integer selected from the group consisting of 74 to 86 and 130 to 137, preferably 80) (B) antigenic peptide residue, and (c) C-terminal partial polypeptide residue of hepatitis B virus core antigen polypeptide (continuous from amino acid residue Y to C terminus of hepatitis B virus core antigen polypeptide) (Con
- the chimeric hepatitis B virus core antigen polypeptide used in the present invention forms core particles by self-assembly with the above-described configuration, and antigenic peptide residues are presented on the outside of the particles.
- the insertion amino acid sequence between component (a) and component (c) is one or more (preferably 1 to 3, more preferably) May contain other antigenic peptide residues. Additional antigenic peptide residues may be inserted at any position between component (a) and component (b), or between component (b) and component (c).
- the length of the further antigenic peptide residue is usually 5-30 amino acids, preferably 6-25 amino acids, more preferably 10-18 amino acids, and even more preferably 11-16 amino acids.
- the antigenic peptide residues may be directly linked by a covalent bond, They may be linked via a spacer sequence.
- spacer sequence is meant an amino acid sequence comprising one or more amino acid residues inserted between two adjacent components contained in a chimeric hepatitis B virus core antigen polypeptide. It is preferable that antigenic peptide residues are linked via a spacer sequence so that a plurality of antigenic peptide residues can be stably presented while maintaining the structure.
- the length of the spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and all antigenic peptide residues inserted outside the particle are presented, Usually 1 to 10 amino acids, preferably 1 to 5 amino acids, more preferably 1 to 3 amino acids, most preferably 2 or 3 amino acids.
- the most N-terminal antigenic peptide residue between component (a) and component (c) and component (a) may be directly covalently linked, or the spacer sequence It may be connected via.
- Component (a) and the most N-terminal side so that the antigenic peptide can be stably presented outside the core particles formed by self-assembly of the chimeric hepatitis B core antigen polypeptide.
- These antigenic peptide residues are preferably linked via a spacer sequence.
- the length of the spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle, but usually 1 to 10 amino acids, preferably Is 1 to 5 amino acids, more preferably 1 to 3 amino acids, most preferably 2 or 3 amino acids.
- the type of spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle. Examples of preferred spacer sequences include IT, GAT, CGG and the like, but are not limited thereto.
- component (a) and component (c) and component (c) may be directly linked by a covalent bond, or a spacer sequence It may be connected via.
- the most antigenic peptide residue on the C-terminal side so that the antigenic peptide can be stably presented outside the core particle formed by self-assembly of the chimeric hepatitis B core antigen polypeptide.
- component (c) are preferably linked via a spacer sequence.
- the length of the spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle, but usually 1 to 10 amino acids, preferably Is 1 to 5 amino acids, more preferably 1 to 3 amino acids, most preferably 2 or 3 amino acids.
- the type of spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle. Examples of preferred spacer sequences include IT, GAT, CGG and the like, but are not limited thereto.
- the length of the inserted amino acid sequence between component (a) and component (c) is such that the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly, and the antigenic peptide is outside the particle. Is not particularly limited as long as it can induce a specific immune response against the antigenic peptide, but it is usually 5 to 80 amino acids. If the inserted amino acid sequence is too short, antigenicity as an epitope may be lost.
- the antigenic peptide and the hepatitis B virus core antigen polypeptide are directly linked by covalent bond. Or may be linked via a spacer sequence.
- the antigenic peptide and the hepatitis B virus core can be stably presented on the outside of the core particles formed by self-assembly of the chimeric hepatitis B virus core antigen polypeptide while maintaining its structure.
- the antigen polypeptide is preferably linked via a spacer sequence.
- the length of the spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle, but usually 1 to 10 amino acids, preferably Is 1 to 5 amino acids, more preferably 1 to 3 amino acids, most preferably 2 or 3 amino acids.
- the type of spacer sequence is not limited as long as the chimeric hepatitis B virus core antigen polypeptide forms a core particle by self-assembly and the antigenic peptide is presented on the outside of the particle.
- the expression vector (II) is a recombinant vector into which a polynucleotide encoding the chimeric hepatitis B virus core antigen polypeptide is incorporated.
- the expression vector is taken into cells of the target mammal, and the cells express the chimeric hepatitis B virus core antigen polypeptide.
- the expression vector into which the polynucleotide encoding the chimeric hepatitis B virus core antigen polypeptide is inserted include plasmids, viruses, phages, cosmids, and other vectors conventionally used in the art.
- Plasmid vectors include pCAGGS (Gene 108: 193-199 (1991)), pCR-X8 (Vaccine 24: 4942-4950 (2006)), pcDNA3.1 (trade name, Invitrogen), pZeoSV (trade name, Invitrogen) And pBK-CMV (trade name, Stratagene), pVAX1 (trade name, Life Technologies), and the like, but are not limited thereto.
- the viral vector is a DNA virus or an RNA virus.
- Viral vectors include detoxified retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus (HVJ), SV40, and human immunodeficiency virus (HIV), etc. However, it is not limited to these. Sendai virus envelope (HVJ-E) Etc. can also be used.
- HVJ-E Sendai virus envelope
- a polynucleotide preferably DNA
- a chimeric hepatitis B virus core antigen polypeptide exhibits promoter activity in the cells of a mammal to be administered (preferably human, dog or cat). It is operably linked to a promoter that can be exerted.
- the promoter used is not particularly limited as long as it can function in mammalian cells to be administered.
- a polI promoter, polII promoter, polIII promoter and the like can be used as the promoter.
- SV40-derived early promoter, viral promoter such as cytomegalovirus LTR, mammalian constituent protein gene promoter such as ⁇ -actin gene promoter, and RNA promoter such as tRNA promoter are used.
- the expression vector preferably contains a transcription termination signal, that is, a terminator region, downstream of the polynucleotide encoding the chimeric hepatitis B virus core antigen polypeptide.
- a selection marker gene for selecting transformed cells a gene that imparts resistance to drugs such as tetracycline, ampicillin, and kanamycin, a gene that complements an auxotrophic mutation, and the like.
- the expression vector may contain an immunostimulatory sequence (ISS) (also referred to as CpG) in order to enhance the immune effect.
- Immunostimulatory sequences are DNA containing bacterial unmethylated CpG motifs and are known to act as ligands for specific receptors (Toll-like receptor 9) (see Biochim. Biophys. Acta 1489, for details). 107-116 (1999) and Curr. Opin. Microbiol. 6, 472-477 (2003)).
- Preferable examples of the immunostimulatory sequence include the following.
- ISS sequences include the following. 5'-ggt gca tcg atg cag ggg gg tga ctg tga acg ttc gag atg a tcg tcg aac gtt cgagat gat tcg aac gtt cga acg ttc gaa cgt t-3 '(SEQ ID NO: 30)
- the preparation of the present invention is a single preparation obtained by simultaneously formulating the antigenic peptide of (I) and the expression vector of (II), the expression of the antigenic peptide of (I) and (II) It may be a combination of two types of preparations obtained by separately formulating a vector.
- the preparation of the present invention is a single preparation obtained by simultaneously formulating the antigenic peptide (I) and the expression vector (II).
- the preparation of the present invention can be provided as a pharmaceutical composition containing an effective amount of the antigenic peptide of (I) and / or the expression vector of (II) and any carrier, for example, a pharmaceutically acceptable carrier. .
- Examples of pharmaceutically acceptable carriers include sucrose, starch, mannitol, sorbit, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, and other excipients, cellulose, methylcellulose, hydroxypropylcellulose, gelatin, arabic Binders such as rubber, polyethylene glycol, sucrose, starch, starch, carboxymethyl cellulose, hydroxypropyl starch, sodium-glycol starch, sodium bicarbonate, calcium phosphate, calcium citrate and other disintegrants, magnesium stearate, aerosil, talc Lubricants such as sodium lauryl sulfate, fragrances such as citric acid, menthol, glycyrrhizin / ammonium salt, glycine, orange powder, sodium benzoate, hydrogen sulfite Preservatives such as thorium, methylparaben, propylparaben, stabilizers such as citric acid, sodium citrate and acetic acid, suspensions
- the preparation of the present invention can be orally or parenterally administered to a mammal to be applied. However, the preparation of the present invention is preferably administered parenterally to a mammal.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions. May contain antioxidants, buffers, antibacterial agents, tonicity agents and the like. Aqueous and non-aqueous sterile suspensions are also included, which may contain suspending agents, solubilizers, thickeners, stabilizers, preservatives and the like.
- the preparation can be enclosed in a container in unit doses or multiple doses such as ampoules, vials, and syringe cartridges.
- the active ingredient and a pharmaceutically acceptable carrier can be lyophilized and stored in a state that may be dissolved or suspended in a suitable sterile vehicle immediately before use.
- the preparation of the present invention encloses an effective amount of the antigenic peptide of (I) and the expression vector of (II), and a pharmaceutically acceptable carrier in a unit dose or multiple doses in a container. Provided as a formulation.
- the preparation of the present invention comprises an effective amount of the antigenic peptide of (I) and a pharmaceutically acceptable carrier enclosed in a container in a unit dose or multiple doses, and an effective amount of ( It is provided as a combination of the expression vector of II) and a pharmaceutically acceptable carrier with a unit dose or multiple doses enclosed in a container.
- the preparation of the present invention may further contain an adjuvant in order to enhance the specific immune response against the antigenic peptide.
- the adjuvant include aluminum hydroxide, complete Freund's adjuvant, incomplete Freund's adjuvant, Bordetella pertussis adjuvant, poly (I: C), CpG-DNA and the like.
- ISS immunostimulatory sequence
- the ISS is not included in the adjuvant mentioned here.
- the preparation of the present invention has an enhanced effect of inducing a specific immune response against the antigenic peptide by combining the antigenic peptide of (I) and the expression vector of (II), the adjuvant as described above Sufficient to induce a specific immune response to the antigenic peptide.
- the formulations of the present invention do not include an adjuvant.
- the uptake of the antigenic peptide of (I) and the expression vector of (II) into the antigen-presenting cell is increased, the presentation of the antigenic peptide by the antigen-presenting cell is promoted, and specific immunity against the antigenic peptide is promoted.
- the preparation of the present invention is preferably administered (injected) intradermally, subcutaneously or intramuscularly.
- the preparation of the present invention may further contain a reagent for nucleic acid introduction.
- the reagents for nucleic acid introduction include lipofectin (trade name, Invitrogen), lipofectamine (trade name, Invitrogen), transfectam (trade name, Promega), DOTAP (trade name, Roche Applied Science), dioctadecylamidoglycyl spermine (DOGS), L -dioleoyl phosphatidyl-ethanolamine (DOPE), dimethyldioctadecyl-ammonium bromide (DDAB), N, N-di-n-hexadecyl-N, N-dihydroxyethylammonium bromide (DHDEAB), Nn-hexadecyl-N, N-dihydroxyethylammonium bromide (HDEAB) , Cationic lipids such as polybrene or poly
- the expression vector (II) may be encapsulated in any known liposome composed of a lipid bilayer such as an electrostatic liposome.
- the liposomes may be fused to a virus such as inactivated Sendai virus (Hemagglutinating virus of Japan; HVJ).
- HVJ-liposomes have a very high fusion activity with respect to cell membranes compared to normal liposomes.
- retronectin, fibronectin, polybrene, or the like can be used as an introduction reagent.
- the preparation of the present invention the effect of inducing a specific immune response against the antigenic peptide is enhanced by combining the antigenic peptide of (I) and the expression vector of (II). Sufficient specific immune responses against antigenic peptides can be induced without the need for introduction reagents. Therefore, in one embodiment, the preparation of the present invention does not contain a nucleic acid introduction reagent. In this embodiment, the uptake of the antigenic peptide of (I) and the expression vector of (II) into the antigen-presenting cell is increased, the presentation of the antigenic peptide by the antigen-presenting cell is promoted, and specific immunity against the antigenic peptide is promoted. From the viewpoint of strongly inducing a response, the preparation of the present invention is preferably administered (injected) intradermally, subcutaneously or intramuscularly.
- the content of the antigenic peptide (I) in the pharmaceutical composition is not particularly limited and is appropriately selected within a wide range, but is usually about 0.0001 to 99% by weight of the whole pharmaceutical composition.
- the content of the expression vector (II) in the pharmaceutical composition is not particularly limited and is appropriately selected within a wide range, but is usually about 0.0001 to 99% by weight of the whole pharmaceutical composition.
- the above numerical range shows that even if the preparation of the present invention is a single preparation obtained by simultaneously formulating the antigenic peptide of (I) and the expression vector of (II), the antigenic peptide of (I) A combination of two types of preparations obtained by separately formulating the expression vector of (II) is also applicable.
- the antigenic peptide (I) and the expression vector (II) are administered substantially simultaneously to the application target.
- “Substantially simultaneous” means that one of the antigenic peptide of (I) or the expression vector of (II) is added before the acquired immune response specific to the antigenic peptide is induced. It means to administer.
- the time difference between the administration of the antigenic peptide of (I) and the administration of the expression vector of (II) is usually within 24 hours Preferably within 12 hours, within 6 hours, within 2 hours, within 1 hour, within 30 minutes, within 15 minutes, within 5 minutes, or within 1 minute, most preferably 0 minutes (simultaneously).
- Boost is not included in “substantially simultaneous” administration.
- the administration form of the antigenic peptide of (I) and the expression vector of (II) is particularly limited as long as the antigenic peptide of (I) and the expression vector of (II) are administered to the application subject substantially simultaneously.
- administration forms include (1) administration of a single preparation obtained by simultaneously formulating the antigenic peptide of (I) and the expression vector of (II), and (2) the antigen of (I) Co-administration of two preparations obtained by separately formulating the sex peptide and the expression vector of (II) by the same administration route, (3) the antigenic peptide of (I) and the expression vector of (II) Administration of two types of preparations obtained by separate formulation with the same administration route with a time difference, (4) Obtained by separately formulating (I) antigenic peptide and (II) expression vector Co-administration of two preparations in different administration routes, (5) Time difference in different administration routes of two preparations obtained by separately formulating (I) antigenic peptide and (II) expression vector (For example, (II)
- a single preparation obtained by simultaneously formulating the antigenic peptide (I) and the expression vector (II) is administered to an application subject.
- the preparation of the present invention may be administered to the administration target mammal by any method as long as it induces a specific immune response against the antigenic peptide.
- the formulations of the invention are administered parenterally in an amount sufficient to induce a specific immune response against the antigenic peptide to the application subject.
- administration via a route within the skin, subcutaneous, intramuscular, intravenous, intraperitoneal, adipose tissue, or mammary tissue; gas-induced particle bombardment (using an electron gun or the like); needleless syringe (spring
- administration methods include administration by formula (eg, Shimajet etc.), explosive formula (eg, Daicel etc.); method via mucosal route in the form of nasal drops and the like.
- the preparation of the present invention is preferably administered (injected) intradermally, subcutaneously or intramuscularly.
- each administration method may be the same or different, but preferably administered by the same method Is done.
- the antigenic peptide (I) and the expression vector (II) are administered intradermally, subcutaneously, or intramuscularly, respectively.
- the administration site of the antigenic peptide of (I) and the expression vector of (II) may be the same or different, but is preferably administered to the same site.
- a single preparation obtained by simultaneously formulating the antigenic peptide of (I) and the expression vector of (II) is administered intradermally, subcutaneously or intramuscularly to the application target.
- the formulations of the invention are administered intradermally, subcutaneously or intramuscularly with a needleless syringe.
- the needleless syringe is preferably a pressure syringe.
- Examples of needleless syringes include Shimajet (trade name, Shimadzu Corporation), Twinjector EZII (trade name, Nippon Chemical Research), Sirijet (trade name, Keystone), ZENEO (trade name, crossject), etc. Although it can, it is not limited to these.
- the preparation of the present invention comprises the antigenic peptide of (I), the expression vector of (II), and a needleless syringe, and the antigenic peptide of (I) and the expression vector of (II) are contained in the syringeless needle. It can be provided as an encapsulated injection formulation.
- the formulations of the invention are administered subcutaneously, intradermally or intramuscularly with a gene gun.
- the antigenic peptide (I) and the expression vector (II) can be coated on carrier particles such as colloidal gold particles introduced into a living body and used for administration.
- carrier particles such as colloidal gold particles introduced into a living body and used for administration.
- Techniques for coating carrier particles with a polynucleotide are known (see, for example, WO93 / 17706).
- a specific immune response against an antigenic peptide can be sufficiently induced by administering to an administration subject without requiring a special instrument or device such as a needleless syringe or a gene gun.
- the antigenic peptide of (I) and the expression vector of (II) are administered intradermally, subcutaneously, or intramuscularly to an application subject by a normal syringe (with a needle).
- the preparation of the present invention may be divided into a plurality of administration targets (for example, 2 to 10 sites) and administered substantially simultaneously.
- a good immune response can be obtained by administering the preparation of the present invention to a plurality of sites.
- the number of administrations of the preparation of the present invention is not particularly limited as long as it induces a specific immune response against the antigenic peptide, and may be administered once or multiple times.
- the preparation of the present invention is divided and administered multiple times substantially simultaneously, the multiple administrations administered substantially simultaneously are collectively counted as one administration of the preparation of the present invention.
- the antigenic peptide of (I) and the expression vector of (II) are administered separately and substantially simultaneously, one administration of the antigenic peptide of (I) and (II) A single administration of the expression vector is counted together with a single administration of the expression vector.
- the preparation of the present invention when administered to a plurality of locations to be administered substantially simultaneously, a plurality of administrations administered substantially simultaneously are collectively counted as one administration.
- the formulation of the present invention is administered multiple times at regular intervals to induce a good immune response.
- the number of times can be appropriately set while monitoring the strength of the immune response, but is usually 2 to 10 times, preferably 2 to 6 times.
- the frequency of administration is usually once a week to once a year, preferably once every 1 to 6 months.
- the preparation of the present invention induces in vivo expression of the chimeric hepatitis B virus core antigen polypeptide by introducing the expression vector of (II) into mammalian tissues (or cells) to be applied.
- a specific immune response to the antigenic peptide preferably, specifically recognizes the antigenic peptide
- Various methods for introducing nucleic acids such as expression vectors into living organisms are known (T. Friedman, Science 244: 1275-1281 (1989)), and in vivo expression of the chimeric hepatitis B virus core antigen polypeptide is described. Any induction method can be adopted as long as it induces and induces a specific immune response to the antigenic peptide (preferably, production of an antibody that specifically recognizes the antigenic peptide).
- Methods for introducing expression vectors into mammalian tissues (or cells) in vivo include internal liposome method, electrostatic liposome method, HVJ-liposome method, HVJ-AVE liposome method, receptor-mediated gene introduction, particle Examples include, but are not limited to, the cancer method, the naked DNA method, the introduction method using a positively charged polymer, and the electroporation method.
- the preparation of the present invention has an effect of inducing a specific immune response against the antigenic peptide by combining the antigenic peptide of (I) and the expression vector of (II). Even a relatively relaxed introduction method such as the DNA (naked DNA) method can sufficiently induce a specific immune response against the antigenic peptide.
- the uptake of the antigenic peptide of (I) and the expression vector of (II) into the antigen-presenting cell is increased, the presentation of the antigenic peptide by the antigen-presenting cell is promoted, and specific immunity against the antigenic peptide is promoted.
- the preparation of the present invention is preferably administered (injected) intradermally, subcutaneously or intramuscularly.
- an effective amount an amount that induces a specific immune response against the antigenic peptide
- an effective amount an amount that induces a specific immune response against the antigenic peptide
- the dose depends on the administration method, the situation of the recipient (sex, age, weight, etc.), immunogenicity in the mammal to which the antigenic peptide is administered, the strength of the control sequence such as the promoter contained in the expression vector, etc.
- a certain amount of the antigenic peptide of (I) and the expression vector of (II) are administered to the mammal to be administered, and the antibody titer specific to the antigenic peptide is measured by an assay method such as ELISA.
- the amount of the antigenic peptide is, for example, The amount is about 1 ⁇ g to 1 mg, preferably about 5 ⁇ g to 50 ⁇ g, but is not limited thereto.
- the amount of the expression vector is, for example, 1 ⁇ g to The amount is about 200 ⁇ g, preferably about 5 ⁇ g to 100 ⁇ g, but is not limited thereto.
- the preparation of the present invention has a synergistic action of “inducing a specific immune response against an antigenic peptide”.
- ⁇ the action of inducing a specific immune response against a synergistic antigenic peptide '' means ⁇ the action of inducing a specific immune response against an antigenic peptide by administration of the antigenic peptide (I) alone '' and ⁇ ( It means “an effect of inducing a specific immune response against an antigenic peptide” exceeding the sum of “an effect of inducing a specific immune response against an antigenic peptide by administration of the expression vector alone in II)”.
- a synergistically effective amount of the antigenic peptide (I) and the expression vector (II) are administered to the application subject.
- an autoantigen protein or a partial peptide thereof which is an antigen contributing to exacerbation of a specific disease (eg, lifestyle-related disease)
- a specific immune response against the partial peptide preferably a specific humoral immune response against the peptide (ie production of an antibody that specifically recognizes the peptide) is induced, and the activity of the autoantigen protein is moderated by the antibody.
- diseases eg, lifestyle-related diseases
- the preparation of the present invention can produce renal failure, heart failure, hypertension, hyperlipidemia, arteriosclerosis (occlusion). Atherosclerosis, etc.), myocardial infarction, cerebral infarction, dementia and the like.
- the preparation of the present invention can be used as a prophylactic or therapeutic agent for hyperlipidemia.
- the preparation of the present invention can prevent or treat cancer (particularly solid cancer), diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc. It can be used as an agent.
- cancer particularly solid cancer
- diabetic retinopathy retinopathy of prematurity
- the preparation of the present invention can be used as a prophylactic or therapeutic agent for arteriosclerosis (particularly atherosclerosis).
- PCSK9 or a partial peptide thereof is used as the antigenic peptide
- the preparation of the present invention can be used as a prophylactic or therapeutic agent for hyper LDL blood.
- the preparation of the present invention can be used as a preventive or therapeutic agent for diabetes and insulin resistance.
- the preparation of the present invention can be used as an agent for preventing or treating autoimmune diseases / inflammatory diseases such as rheumatism, SLE and ulcerative colitis; and cancer .
- the preparation of the present invention has an excellent effect as a preventive or therapeutic agent for canine heart failure.
- the left ventricle is often thickened and hardened due to hypertension, resulting in diastolic dysfunction.
- valvular disease often prevents the mitral valve from closing properly. The cause of this is that the delivery of is worsened and the burden on the heart is increased.
- the present inventors have found that the preparation of the present invention is extremely effective for heart failure due to such valvular disease (mitral regurgitation).
- the preparation of the present invention using angiotensin II or a partial peptide thereof as an antigenic peptide for such subjects.
- angiotensin II or a partial peptide thereof By administering an effective amount, heart failure caused by mitral regurgitation can be prevented.
- an effective amount of the preparation of the present invention using angiotensin II or a partial peptide thereof to a subject (eg, dog) who has developed heart failure due to mitral regurgitation the heart failure Can be treated.
- angiotensin II In renal failure (especially feline renal failure), angiotensin II is considered to be caused by an increase in glomerular blood pressure and glomerular hypertrophy.
- angiotensin II and its The effectiveness of the preparation of the present invention using a partial peptide can be expected.
- a neutralizing antibody against an antigen that contributes to the exacerbation of the disease is induced, and the onset of the disease is prevented. I can do it.
- the preparation of the present invention when used for the purpose of prevention or treatment of a specific disease, is a prophylactic or therapeutically effective amount of the disease (preferably a synergistic preventive or therapeutically effective amount). Is administered to the subject of application.
- the dosage of pcDNA3.1-HBc-AngII is 1.2 mg / time / animal. This administration was performed twice on day 0 and day 14.
- the CpG DNA used is a 1: 1 mixture of single-stranded DNA consisting of the following two sequences. No. 2006: TCGTCGTTTTGTCGTTTTCTCGTT (SEQ ID NO: 31) No. YW07: TCGTCGTTAACGTTAACGCTA (SEQ ID NO: 32) (III) pcDNA3.1-HBc-AngII prepared to 3 mg / 2 ml was injected into the dog muscle at one location together with CpG DNA (total dose 160 ⁇ g / time / animal). The dosage of pcDNA3.1-HBc-AngII is 3.0 mg / time / animal. This administration was performed twice on day 0 and day 14.
- Intramuscular administration of pcDNA3.1-HBc-AngII hardly increased the antibody titer against angiotensin II.
- a slight increase in the antibody titer against angiotensin II was observed 6 weeks after administration with shimajet.
- Example 1 Increased antibody titer by DNA + peptide combination vaccine
- pcDNA3.1-HBc-AngII prepared at 250 ⁇ g / 100 ⁇ l, together with CpG DNA (total dose 40 ⁇ g / time / animal), 4 sites per administration, using shimajet in dog skin Administered.
- the dosage of pcDNA3.1-HBc-AngII is 1.0 mg / time / animal.
- AngII-KLH prepared to 12.5 ⁇ g / 250 ⁇ l was administered into the skin of dogs at two sites per administration together with CpG DNA (total dose 40 ⁇ g / time / animal). The dose of AngII-KLH is 25 ⁇ g / time / animal. This administration was performed three times on day 0, day 14 and day 42.
- the antibody titer increased by booster immunization at 20 weeks was lower than the peak after the third administration.
- the booster effect was stronger in the combination group (III) than in the peptide-only administration group (II).
- dMAP mean blood pressure
- dLAP left atrial pressure
- dSVR systemic vascular resistance
- dCO cardiac output
- Test group (I) pcDNA3.1-HBc-AngII + AngII-KLH (Simajet, intradermal) (II) pcDNA3.1-HBc + AngII-KLH (Simajet, intradermal) (III) AngII-KLH (Simajet, intradermal) (IV) pcDNA3.1-HBc-AngII + AngII-KLH (intramuscular) (V) Freund's adjuvant + AngII-KLH (subcutaneous) In any case, on day 0, day 14 and day 28, administration / evaluation items The time course of antibody titer against angiotensin II in peripheral blood was measured.
- the DNA + peptide combination vaccine showed an increase in the anti-angiotensin II antibody titer even after single administration, which was higher than that of the peptide alone administration group.
- the increase in antibody titer persisted for a longer time in the DNA + peptide combination vaccine than in the peptide alone administration group (FIGS. 8 to 10).
- mVEGF peptide IMRIKPHQSQHIG (SEQ ID NO: 1)
- Test group II) pcDNA3.1-HBc-mVEGF (2 mg / ml, 60 ⁇ l) + mVEGF-KLH (1 mg / ml, 10 ⁇ l) (intramuscular administration, 35 ⁇ l for each foot) (with electroporation)
- II Saline (60 ⁇ l) + mVEGF-KLH (1mg / ml, 10 ⁇ l) (Intramuscular administration, 35 ⁇ l for each foot) (with electroporation)
- III pcDNA3.1-HBc-mVEGF (2 mg / ml, 60 ⁇ l) + mVEGF-KLH (1 mg / ml, 10 ⁇ l) (intramuscular administration, 35 ⁇ l for each foot) (no electroporation)
- Evaluation item The time course of antibody titer against VEGF in
- Test group Group 1 pcDNA3.1-HBc-AngII (200 ⁇ g) + AngII-KLH (5 ⁇ g)
- Group 2 pVAX1-HBc-AngII (200 ⁇ g) + AngII-KLH (5 ⁇ g)
- Group 3 pVAX1-HBc-AngII (40 ⁇ g) + AngII-KLH (5 ⁇ g)
- Group 4 pVAX1-HBc-AngII (8 ⁇ g) + AngII-KLH (5 ⁇ g) Evaluation items The antibody titer against AngII in peripheral blood was measured.
- Example 7 Comparison of aspects of conjugation of AngII peptide to KLH in DNA + peptide combination vaccine Using three types of AngII-KLH conjugates, vaccination with DNA + peptide combination using the following protocol and antibody titer against angiotensin II in peripheral blood The effect on was compared.
- Test material (1) Test substance 1: Angiotensin II vaccine 1 A solution containing KLH-AngII conjugate (prepared by the glutaraldehyde method) and pVAX1-HBc-AngII (saline). (2) Test substance 2: Angiotensin II vaccine 2 A solution containing KLH-Cys-AngII conjugate (prepared by Sulpho-GMBS method) and pVAX1-HBc-AngII (saline). (3) Test substance 3: Angiotensin II vaccine 3 A solution (physiological saline) containing KLH-Cys-Gly-Gly-AngII conjugate (prepared by Sulpho-GMBS method) and pVAX1-HBc-AngII.
- Each vaccine solution was administered at a dose of 200 ⁇ L / animal into a rat thigh muscle using a polypropylene syringe and a 27G needle.
- Antibody titer The antibody titer against AngII peptide in serum at 2 weeks and 4 weeks after vaccine administration was higher than that before administration in any group. Significantly high values were shown in the low dose group and high dose group of angiotensin II vaccine 1 (p ⁇ 0.01, FIGS. 13-1, 13-2, 14-1 and 14-2).
- Example 8 Effect of DNA + peptide combination vaccine on blood pressure in SHR rats (measured by telemetry) According to the following protocol, SHR / Izm rats were implanted with a telemetry transmitter for blood pressure measurement, and the effect of DNA + peptide combination vaccine administration on blood pressure was evaluated.
- Test schedule The test was conducted according to the schedule shown in FIG.
- the vaccine solution was administered at a dose of 200 ⁇ L / animal into a rat thigh muscle using a polypropylene syringe and a 27G needle.
- Rats were anesthetized by implantation of ketamine hydrochloride and xylazine intramuscularly in a telemetry transmitter.
- the femoral artery was exposed and a catheter of a telemetry transmitter (TA11PA-C40, DSI) was placed in the blood vessel.
- the telemetry transmitter body was placed in the abdominal cavity and the wound was sutured.
- Blood pressure and heart rate measurement measurement period From 1 week before vaccine administration (10 days before) to 5 weeks after (35 days). Measurement items: systolic blood pressure, diastolic blood pressure, average blood pressure, heart rate (calculated from blood pressure pulse wave) Measurement method: A blood pressure signal sent from a telemetry transmitter implanted in a rat was received by a receiving board (RPC-1, Data Sciences International) and incorporated into a chronic experimental telemetry automatic measurement system (Ponemah Physiology Platform 5.0). Data acquisition: Data was continuously acquired during the measurement period, and the data was stored in a timely manner. Sampling time: Blood pressure and heart rate were calculated as average values every hour.
- Blood collection time Before vaccine administration (when the sensor is implanted), 2 weeks and 5 weeks after vaccine administration
- Blood collection method Under isoflurane inhalation anesthesia, approximately 0.5 mL of blood is collected from the rat jugular vein and placed in a blood collection tube containing EDTA Stir. The blood was centrifuged (3000 rpm, 10 minutes, 4 ° C.) to collect plasma. The collected plasma was stored frozen at -80 ° C.
- Results Effect on blood pressure Continuous blood pressure and heart rate data extracted for 10 minutes during the active period (nighttime) and inactive period (daytime) for each individual before and 2 weeks after vaccine administration. -1 to Figure 16-3.
- the systolic blood pressure, the diastolic blood pressure, the average blood pressure, and the heart rate were significantly reduced by the vaccine administration.
- the systolic blood pressure during the night (active period) and the tendency to decrease the heart rate were also observed by vaccine administration.
- FIG. 17 shows the results of measuring the antibody titer (absorbance) against the AngII peptide by enzyme immunoassay using plasma diluted 250-fold.
- an increase in antibody titer against AngII peptide was observed at 2 weeks and 5 weeks after vaccine administration.
- the antibody titer against the AngII peptide was low, and a correlation between the blood pressure lowering effect and the antibody titer against the AngII peptide was observed.
- a vaccine capable of strongly inducing a specific antibody against an antigenic peptide.
- a specific antibody against an antigenic peptide can be effectively induced using a DNA vaccine without requiring treatment such as electroporation or a nucleic acid introduction reagent.
- the increase in the antibody titer of the specific antibody against the antigenic peptide persists for a long period of time, so that the number of vaccine administrations can be reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
[1]抗原性ペプチドに対する特異的免疫応答を誘導するための組み合わせ製剤であって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、且つ
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、製剤。
[2]キメラB型肝炎ウイルスコア抗原ポリペプチドにおいて、抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基80と81の間に挿入されている、[1]記載の製剤。
[3]単一の製剤として製剤化されている、[1]又は[2]記載の製剤。
[4](I)のペプチドと、(II)の発現ベクターとが適用対象に対して同一投与経路で投与される、[1]~[3]のいずれか記載の製剤。
[5]皮下、皮内、又は筋肉内に投与される[4]記載の製剤。
[6]投与回数が1回である、[1]~[5]のいずれか記載の製剤。
[7]投与にエレクトロポレーション及び/又は核酸導入用試薬を用いない、[1]~[6]のいずれか記載の製剤。
[8]アジュバントを含まない、[1]~[7]のいずれか記載の製剤。
[9]抗原性ペプチドが、適用対象の自己抗原タンパク質又はその部分ペプチドである、[1]~[8]のいずれか記載の製剤。
[10]自己抗原タンパク質が、疾患の増悪に寄与する抗原である、[9]記載の製剤。
[11]疾患が生活習慣病である、[10]記載の製剤。
[12]自己抗原タンパク質が、アンギオテンシンIIである、[10]又は[11]記載の製剤。
[13]心不全、高血圧症、腎不全、動脈硬化、心筋梗塞、脳梗塞、閉塞性動脈硬化症、又は認知症の治療又は予防用である、[12]記載の製剤。
[14]僧房弁閉鎖不全症に起因する心不全の治療又は予防用である、[13]記載の製剤。
[15]自己抗原タンパク質が、VEGFである、[10]又は[11]記載の製剤。
[16]癌、糖尿病性網膜症、加齢黄斑変性症、又は未熟児網膜症の治療又は予防用である、[15]記載の製剤。
[17]適用対象がヒトである、[1]~[16]のいずれか記載の製剤。
[18]適用対象が非ヒト哺乳動物である、[1]~[16]のいずれか記載の製剤。
[19]適用対象に対して、抗原性ペプチドに対する特異的免疫応答を誘導するための方法であって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を、実質的に同時に投与することを含む、方法。
[20]抗原性ペプチドに対する特異的免疫応答の誘導において使用するための、組み合わせであって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、組み合わせ。
[21]抗原性ペプチドに対する特異的免疫応答を誘導するための医薬の製造における、組み合わせの使用であって、該組み合わせは、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、使用。
本発明により、エレクトロポレーションや核酸導入試薬等の処置を要せずとも、DNAワクチンを用いて、抗原性ペプチドに対する特異的抗体を効果的に誘導することができる。
また、本発明により、抗原性ペプチドに対する特異的抗体の抗体価の上昇が長期間持続するので、ワクチン投与の回数を減らすことが出来る。
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含む、製剤を提供するものである。
a)IMRIKPHQSQHIG(配列番号1)
b)MRIKPHQ(配列番号2)
c)MQIMRIKPHQSQHIGEM(配列番号3)
d)配列番号1又は2で表されるアミノ酸配列を含む、配列番号3で表されるアミノ酸配列の部分配列からなるペプチド
e)IMRIKPHQGQHIG(配列番号4)
f)MRIKPHQ(配列番号5)
g)MQIMRIKPHQGQHIGEM(配列番号6)
h)配列番号4又は5で表されるアミノ酸配列を含む、配列番号6で表されるアミノ酸配列の部分配列からなるペプチド
a)PQRQNTNKFNGIKWYY(配列番号7)
b)YYPQRQNTNKE(配列番号8)
a)CGGDRVYIHPF(配列番号9)
b)CGGDRVYIHPFHL(配列番号10)
c)DRVYIHPFHLGGC(配列番号11)
d)CDRVYIHPFHL(配列番号12)
e)CHPFHL(配列番号13)
f)CGPFHL(配列番号14)
g)CYIHPF(配列番号15)
h)CGIHPF(配列番号16)
i)CGGHPF(配列番号17)
j)CRVYIGGC(配列番号18)
k)DRVYGGC(配列番号19)
l)DRVGGC(配列番号20)
m)DRVYIHPF(配列番号21)
a)~l)は、アンギオテンシンIIの部分アミノ酸配列を含むペプチドである。m)は、アンギオテンシンIIの全長ペプチドである。好ましくはDRVYIHPF(配列番号21)を抗原性ペプチドとして用いる。該ペプチドを用いるとアンギオテンシンIよりもアンギオテンシンIIに特異性の高い抗体が誘導される。尚、アンギオテンシンIIのアミノ酸配列は、ヒト、イヌ、ネコ、マウス、及びラットにおいて共通しているので、a)~m)の各ペプチドは、ヒトのみならず、イヌ、ネコ、マウス、及びラットへも適用可能である。
a)RDGFLLLQMDFGFPEHLLVDFLQSL(配列番号22)
a)は、ヒト、マウス及びラビットのCETPの部分ペプチドである。
a)EAPSEQAPTEQR(配列番号23)
a)SKDEAAADSRRT(配列番号33)
b)KSTFRVKSYS(配列番号34)
c)ENSTFESFG(配列番号35)
a)~c)は、マウスDPP4の部分ペプチドである(a:29-40aa、b:48-57aa、c:89-97aa)。
a)SSACPNTEAKD(配列番号36)
b)KVSSRRPSDYLNRSTS(配列番号37)
c)HRNEDPDRYPSVIWE(配列番号38)
d)KREPESCPFT(配列番号39)
e)EKMLVGVGCTCVASI(配列番号40)
a)~e)は、マウスIL-17の部分ペプチドである。
(1)配列番号24で表されるアミノ酸配列を含むポリペプチド、又は
(2)配列番号24で表されるアミノ酸配列と90%以上(好ましくは95%以上、より好ましくは97%以上、更に好ましくは99%以上)の同一性を有するアミノ酸配列を含み、且つ自己集合によりコア粒子を形成する活性を有するポリペプチド
である。
(a)B型肝炎ウイルスコア抗原ポリペプチドのN末端部分ポリペプチド残基(B型肝炎ウイルスコア抗原ポリペプチドのN末端からアミノ酸残基Xまでの連続する部分アミノ酸配列からなる)(ここで、Xは74~86及び130~137からなる群から選択されるいずれかの整数であり、好ましくは80である)、
(b)抗原性ペプチド残基、及び
(c)B型肝炎ウイルスコア抗原ポリペプチドのC末端部分ポリペプチド残基(B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基YからC末端までの連続する部分アミノ酸配列からなる)(ここで、YはXに1を加えた整数であり、好ましくは81である)
をN末端側から(a)、(b)、(c)の順序で含む。
等も利用できる。
CpG-B1018 22bp
5’-tga ctg tga acg ttc gag atg a-3’(配列番号26)
CpG-A D19 20bp (D type)
5’-ggt gca tcg atg cag ggg gg-3’(配列番号27)
CpG-CC274 21bp
5’-tcg tcg aac gtt cga gat gat-3’(配列番号28)
CpG-CC695 25bp
5’-tcg aac gtt cga acg ttc gaa cgt t-3’(配列番号29)
5’-ggt gca tcg atg cag ggg gg tga ctg tga acg ttc gag atg a tcg tcg aac gtt cgagat gat tcg aac gtt cga acg ttc gaa cgt t-3’(配列番号30)
ワクチン投与によるアンギオテンシンIIに対する抗体価の上昇
(方法)
PCR及びライゲーションにより、HBcのアミノ酸残基80と81の間に、スペーサー配列およびアンギオテンシンIIのアミノ酸配列DRVYIHPF(配列番号21)が挿入された、改変HBcをコードするDNA断片を得た。このDNA断片をpcDNA 3.1/V5-His TOPO TA Expression Kit (Invitrogen)にTAクローニングすることによりpcDNA3.1-HBc-AngII ベクターを得た。
6匹の犬を3群に分け(1群あたりn=2)、pcDNA3.1-HBc-AngIIにより、以下の3つのプロトコールで免疫し、免疫開始日を0日目として、0日目、4週間後、及び6週間後に、末梢血のアンギオテンシンIIに対する抗体価を測定した。
(I)100μg/100μlに調製したpcDNA3.1-HBc-AngIIを、1回の投与につき、4箇所、針無注射器 シマジェット(商品名、島津製作所)を用いてイヌの皮内に投与した。投与量は0.4 mg/time/匹である。この投与を0日目及び14日目の2回行った。
(II)150μg/100μlに調製したpcDNA3.1-HBc-AngIIを、CpG DNA(総投与量 160μg/time/匹)と共に、1回の投与につき、8箇所、シマジェットを用いてイヌの皮内に投与した。pcDNA3.1-HBc-AngIIの投与量は1.2 mg/time/匹である。この投与を0日目及び14日目の2回行った。使用したCpG DNAは、以下の2つの配列からなる1本鎖DNAの1:1混合物である。
No. 2006: TCGTCGTTTTGTCGTTTTCTCGTT(配列番号31)
No. YW07: TCGTCGTTAACGTTAACGCTA (配列番号32)
(III)3mg/2mlに調製したpcDNA3.1-HBc-AngIIを、CpG DNA(総投与量 160μg/time/匹)と共に、イヌの筋肉内に1箇所注射した。pcDNA3.1-HBc-AngIIの投与量は3.0 mg/time/匹である。この投与を0日目及び14日目の2回行った。
pcDNA3.1-HBc-AngIIの筋肉内投与によっては、アンギオテンシンIIに対する抗体価はほとんど上昇しなかった。シマジェットによる投与の6週間後において、アンギオテンシンIIに対する抗体価の若干の上昇を認めた。
DNA+ペプチド併用ワクチンによる抗体価の上昇
8匹の犬を4群に分け(1群あたりn=2)、pcDNA3.1-HBc-AngII及びアンギオテンシンIIの部分ペプチドとKLHとのコンジュゲート(AngII-KLH)により、以下の4つのプロトコールで免疫し、経時的に、末梢血のアンギオテンシンIIに対する抗体価を測定した。
(I)250μg/100μlに調製したpcDNA3.1-HBc-AngIIを、CpG DNA(総投与量 40μg/time/匹)と共に、1回の投与につき、4箇所、シマジェットを用いてイヌの皮内に投与した。pcDNA3.1-HBc-AngIIの投与量は1.0 mg/time/匹である。この投与を0日目、14日目及び42日目の3回行った。(DNA単独投与群1)
(II)12.5μg/250μlに調製したAngII-KLHを、CpG DNA(総投与量 40μg/time/匹)と共に、1回の投与につき、2箇所、イヌの皮内に投与した。AngII-KLHの投与量は25 μg/time/匹である。この投与を0日目、14日目及び42日目の3回行った。(ペプチド単独投与群)
(III)pcDNA3.1-HBc-AngII終濃度250μg/100μl、及びAngII-KLH終濃度6.25μg/100μlに調製した溶液を、CpG DNA(総投与量 40μg/time/匹)と共に、1回の投与につき、4箇所、シマジェットを用いてイヌの皮内に投与した。pcDNA3.1-HBc-AngIIの投与量は1.0 mg/time/匹であり、AngII-KLHの投与量は25 μg/time/匹である。この投与を0日目、14日目及び42日目の3回行った。(DNA+ペプチド併用群)
(IV)250μg/100μlに調製したpcDNA3.1-HBc-AngIIを、CpG DNA(総投与量 80μg/time/匹)と共に、1回の投与につき、8箇所、シマジェットを用いてイヌの皮内に投与した。pcDNA3.1-HBc-AngIIの投与量は2.0 mg/time/匹である。この投与を0日目、14日目、28日目及び42日目の4回行った。(DNA単独投与群2)
ペプチド単独投与群(II)及びDNA+ペプチド併用群(III)において、アンギオテンシンIIに対する抗体価の上昇を認めた(図1)。特に、併用群(III)において、抗体価の上昇が顕著であった。
イヌ心不全モデルに対するDNA+ペプチド併用ワクチンの効果
(方法)
以下のプロトコールでDNA+ペプチド併用ワクチンの効果を検討した。
・イヌ:n=3
・心不全モデル:ワクチン投与開始の4週間前に、僧房弁の腱索断裂手術を施行して僧房弁閉鎖不全症を生じさせることによりイヌ心不全モデルを作成した。
・ワクチン:pcDNA3.1-HBc-AngII+AngII-KLH
・投与スケジュール
(I)ワクチン投与群
[(pcDNA3.1-HBc-AngII終濃度250μg/100μl+AngII-KLH 終濃度6.25μg/100μl)×4箇所(DNA 1 mg +ペプチド 25μg)+CpG(投与量 40μg/time/匹)]×3回(0日目、14日目、及び42日目)(シマジェット)
(II)コントロール群
生理食塩水×4箇所×3回(0日目、14日目、及び42日目)(シマジェット)
・評価項目
末梢血のアンギオテンシンIIに対する抗体価の経時変化を測定した。
また、心不全のパラメーターとして、平均血圧の変化量(dMAP)、左房圧の変化量(dLAP)、体血管抵抗の変化量(dSVR)及び心拍出量の変化量(dCO)の経時変化を測定した。血圧、LAPはテレメトリーにより測定した。COは心エコーにより計測した。
ワクチン投与群(No. 2, 4, 6)において、アンギオテンシンIIに対する抗体価の有意な上昇を認めた(図5)。
ワクチン投与群において、血圧低下傾向とともに、心不全パラメーターの改善傾向を認めた(図6)。
SHRラットに対するDNA+ペプチド併用ワクチンの効果
以下のプロトコールでDNA+ペプチド併用ワクチンの効果を検討した。
・SHRラット(高血圧自然発症ラット):n=3
・ワクチン:pcDNA3.1-HBc-AngII及び/又はAngII-KLH
コントロールベクターとして、AngIIペプチドの挿入を含まないpcDNA3.1-HBcを用いた。
・試験群
(I) pcDNA3.1-HBc-AngII + AngII-KLH (シマジェット、皮内)
(II) pcDNA3.1-HBc + AngII-KLH (シマジェット、皮内)
(III) AngII-KLH (シマジェット、皮内)
(IV) pcDNA3.1-HBc-AngII + AngII-KLH (筋肉内)
(V) フロイントアジュバント + AngII-KLH (皮下)
いずれも、0日目、14日目、及び28日目に投与
・評価項目
末梢血のアンギオテンシンIIに対する抗体価の経時変化を測定した。
pcDNA3.1-HBc-AngIIとAngII-KLHとの併用により、AngII-KLH単独投与時よりもアンギオテンシンIIに対する抗体価が顕著に上昇した。DNA+ペプチド併用ワクチンは、シマジェット(皮内投与)のみならず、筋肉内投与でも有効であった。抗体価の上昇は、DNA+ペプチド併用ワクチンの方が、ペプチド単独投与群よりも長期間持続する傾向が認められた(図7)。
DNA+ペプチド併用ワクチン単回投与の免疫効果
(方法)
以下のプロトコールでDNA+ペプチド併用ワクチンの単回投与による免疫効果を検討した。
・SHRラット(高血圧自然発症ラット):n=3
・ワクチン:pcDNA3.1-HBc-AngII+AngII-KLH
・試験群
(I) pcDNA3.1-HBc-AngII + AngII-KLH(1μg) (シマジェット、皮内)
(II) pcDNA3.1-HBc-AngII + AngII-KLH(5μg) (シマジェット、皮内)
(III) pcDNA3.1-HBc-AngII + AngII-KLH(20μg)(シマジェット、皮内)
(IV) AngII-KLH(1μg) (シマジェット、皮内)
(V) AngII-KLH(5μg) (シマジェット、皮内)
(VI) AngII-KLH(20μg)(シマジェット、皮内)
いずれも、単回投与(0日目)。
・評価項目
末梢血のアンギオテンシンIIに対する抗体価の経時変化を測定した。
DNA+ペプチド併用ワクチンは、単回投与でも、ペプチド単独投与群よりも高い、抗アンギオテンシンII抗体価の上昇を認めた。抗体価の上昇は、DNA+ペプチド併用ワクチンの方が、ペプチド単独投与群よりも長期間持続した(図8~10)。
DNA+ペプチド併用ワクチンの免疫効果
(方法)
以下のプロトコールでDNA+ペプチド併用ワクチンの免疫効果を検討した。
・Balb/caマウス(雌、6週齢(ワクチン投与開始時において)):n=6
・ワクチン:pcDNA3.1-HBc-mVEGF+-mVEGF-KLH
WO 2014/034735 A1を参照のこと。
mVEGFペプチド:IMRIKPHQSQHIG(配列番号1)
・試験群
(I) pcDNA3.1-HBc-mVEGF(2mg/ml, 60μl)+mVEGF-KLH(1mg/ml, 10μl) (足筋肉内投与、各足35μl)(エレクトロポレーションあり)
(II) 生理食塩水(60μl)+mVEGF-KLH(1mg/ml, 10μl) (足筋肉内投与、各足35μl)(エレクトロポレーションあり)
(III) pcDNA3.1-HBc-mVEGF(2mg/ml, 60μl)+mVEGF-KLH(1mg/ml, 10μl) (足筋肉内投与、各足35μl)(エレクトロポレーションなし)
0日目及び14日目に計2回投与。
・評価項目
末梢血のVEGFに対する抗体価の経時変化を測定した。
DNA+ペプチド併用ワクチンを用いることにより、エレクトロポレーションを用いることなく、VEGFに対する抗体価の上昇を認めた。エレクトロポレーションなしの群(III)の方が、エレクトロポレーションありの群(I)よりも、むしろVEGFに対する抗体価が高かった(図11)。
DNA+ペプチド併用ワクチンの免疫効果
(方法)
以下のプロトコールでpVAX1ワクチンとpcDNA3.1ワクチンの薬効を比較した。
・SHRラット:n=5~6
・各群共に薬剤(200μl)を大腿筋肉に単回筋肉内投与し、投与日(投与直前)、投与2、4、8、12週後に採血を行った。
・試験群
1群:pcDNA3.1-HBc-AngII(200μg)+AngII-KLH(5μg)
2群:pVAX1-HBc-AngII(200μg)+AngII-KLH(5μg)
3群:pVAX1-HBc-AngII(40μg)+AngII-KLH(5μg)
4群:pVAX1-HBc-AngII(8μg)+AngII-KLH(5μg)
・評価項目
末梢血のAngIIに対する抗体価を測定した。
DNA+ペプチド併用ワクチンにおいて、ベクターとして、pVAX1を用いた場合でも、pcDNA3.1を用いた場合と同程度の抗体価の上昇が認められた(図12)。ベクター投与量を200μgよりも少なくすることができる可能性が示された。投与後の早い段階(2、4週)では、各群の抗体価に大きな違いはないが、DNAワクチンの投与量が多い程、高い抗体価がより長い期間持続することが示唆された。
DNA+ペプチド併用ワクチンにおける、AngIIペプチドのKLHへのコンジュゲートの態様の比較
3種類のAngII-KLHコンジュゲートを用いて、以下のプロトコールでDNA+ペプチド併用ワクチン接種を行い、末梢血のアンギオテンシンIIに対する抗体価への効果を比較した。
SDラット(雄性、8週齢(投与時)、日本エスエルシー株式会社):n=6
(1)被検物質1:アンギオテンシンIIワクチン1
KLH-AngIIコンジュゲート(グルタルアルデヒド法により調製)及びpVAX1-HBc-AngIIを含有する溶液(生理食塩水)。
(2)被検物質2:アンギオテンシンIIワクチン2
KLH-Cys-AngIIコンジュゲート(Sulpho-GMBS法により調製)及びpVAX1-HBc-AngIIを含有する溶液(生理食塩水)。
(3)被検物質3:アンギオテンシンIIワクチン3
KLH-Cys-Gly-Gly-AngIIコンジュゲート(Sulpho-GMBS法により調製)及びpVAX1-HBc-AngIIを含有する溶液(生理食塩水)。
(1)アンギオテンシンIIワクチン1、低用量、n=6。
(2)アンギオテンシンIIワクチン1、高用量、n=6。
(3)アンギオテンシンIIワクチン2、低用量、n=6。
(4)アンギオテンシンIIワクチン2、高用量、n=6。
(5)アンギオテンシンIIワクチン3、低用量、n=6。
(6)アンギオテンシンIIワクチン3、高用量、n=6。
各ワクチン溶液を、200μL/匹の用量で、ポリプロピレン製注射筒及び27G注射針を用いて、ラットの大腿筋肉内へ単回投与した。
(1)プラスミドDNA濃度測定用血液
被検物質投与約4時間後に、3.0%イソフルラン吸入麻酔下で頸静脈より血液を約0.4mL採血した。予め100mmol/L EDTAを60μL添加したチューブに血液300μLを採取した。血液は液体窒素により直ちに凍結し、測定時まで-80℃にて冷凍保存した。
(2)抗体価測定用血清
被検物質投与前日、被検物質投与2及び4週間後に3.0%イソフルラン吸入麻酔下で頸静脈より血液約500μLを微量採血管(キャピジェクト、テルモ株式会社)に採取し、遠心機を用いて遠心分離(1800g、室温、10分)し、血清を得た。血清は測定時まで-80℃にて冷凍保存した。
(1)抗体価測定
ワクチン投与前、投与後2週間及び4週間の血清中のAngIIペプチドに対する抗体価を酵素免疫測定法により測定した。
(2)プラスミドDNA濃度測定
ワクチン投与後4時間の血液中プラスミド濃度を定量的PCRにより測定した。定量的PCRには、プラスミドを特異的に検出する、69bpを増幅領域とするプライマーセットを用いた。
(1)抗体価
ワクチン投与2週間及び4週間の血清中のAngIIペプチドに対する抗体価は、いずれの群においても投与前よりも上昇が認められた。アンギオテンシンIIワクチン1の低用量群及び高用量群で有意な高値を示した(p<0.01、図13-1、13-2、14-1及び14-2)。
ワクチン投与後4時間の血液中プラスミド濃度(コピー/μL血液)を、以下の表に示す。いずれの群においても、顕著な差は認められなかった。
SHRラットの血圧に対するDNA+ペプチド併用ワクチンの効果(テレメトリーによる測定)
以下のプロトコールに沿って、SHR/Izmラットに血圧測定用のテレメトリー送信機を埋め込み、DNA+ペプチド併用ワクチン投与の血圧に対する影響を評価した。
図15に記載したスケジュールに沿って、試験を実施した。
SHR/Izmラット(雄性、21週齢(ワクチン投与時)、日本エスエルシー株式会社) 3匹。
KLH-AngIIコンジュゲート(50μg/200μL)及びHBc-AngII発現ベクター(pVAX1-HBc-AngII:200μg/200μL)を含有する溶液。
ワクチン溶液を、200μL/匹の用量で、ポリプロピレン製注射筒及び27G注射針を用いて、ラットの大腿筋肉内へ単回投与した。
塩酸ケタミン及びキシラジン筋肉内投与により、ラットに麻酔を施した。大腿動脈を露出し、テレメトリー送信機(TA11PA-C40、DSI社)のカテーテルを血管内に留置した。テレメトリー送信機本体を腹腔内に留置し、傷口を縫合した。
測定期間:ワクチン投与1週前(10日前)から5週後(35日後)まで。
測定項目:収縮期血圧、拡張期血圧、平均血圧、心拍数(血圧脈波より算出)
測定方法:ラットに埋め込んだテレメトリー送信器から送られてくる血圧の信号を受信ボード(RPC-1、Data Sciences International)で受信し、慢性実験テレメトリー自動計測システム(Ponemah Physiology Platform 5.0)に取り込んだ。
データの取り込み:測定期間中は連続的にデータを取り込み、適時データを保存した。
サンプリング時間:血圧及び心拍数は1時間毎の平均値を算出した。
採血時期:ワクチン投与前(センサー埋め込み時)、ワクチン投与2週後及び5週後
採血方法:イソフルラン吸入麻酔下で、ラット頸静脈より約0.5 mL採血し、EDTA入りの採血管に入れて撹拌した。血液を遠心分離(3000 rpm、10分、4℃)して血漿を回収した。回収した血漿は、-80℃にて凍結保存した。
ワクチン投与前、投与後2週間及び5週間後の血漿中のAngIIペプチドに対する抗体価を酵素免疫測定法により測定した。
(1)血圧に対する効果
ワクチン投与前及びワクチン投与2週間後における、各個体の、活動期(夜間)及び非活動期(昼間)において10分間抽出した血圧及び心拍数の連続データを図16-1~図16-3に示す。
250倍希釈した血漿を用いて、AngIIペプチドに対する抗体価(吸光度)を酵素免疫測定法により測定した結果を図17に示す。いずれの個体においても、ワクチン投与2週間及び5週間後において、AngIIペプチドに対する抗体価の上昇が認められた。血圧低下効果の低かったNo.3の個体では、AngIIペプチドに対する抗体価も低く、血圧低下効果とAngIIペプチドに対する抗体価との間の相関が認められた。
本発明により、エレクトロポレーションや核酸導入試薬等の処置を要せずとも、DNAワクチンを用いて、抗原性ペプチドに対する特異的抗体を効果的に誘導することができる。
また、本発明により、抗原性ペプチドに対する特異的抗体の抗体価の上昇が長期間持続するので、ワクチン投与の回数を減らすことが出来る。
Claims (21)
- 抗原性ペプチドに対する特異的免疫応答を誘導するための組み合わせ製剤であって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、且つ
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、製剤。 - キメラB型肝炎ウイルスコア抗原ポリペプチドにおいて、抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基80と81の間に挿入されている、請求項1記載の製剤。
- 単一の製剤として製剤化されている、請求項1又は2記載の製剤。
- (I)のペプチドと、(II)の発現ベクターとが適用対象に対して同一投与経路で投与される、請求項1~3のいずれか1項記載の製剤。
- 皮下、皮内、又は筋肉内に投与される請求項4記載の製剤。
- 投与回数が1回である、請求項1~5のいずれか1項記載の製剤。
- 投与にエレクトロポレーション及び/又は核酸導入用試薬を用いない、請求項1~6のいずれか1項記載の製剤。
- アジュバントを含まない、請求項1~7のいずれか1項記載の製剤。
- 抗原性ペプチドが、適用対象の自己抗原タンパク質又はその部分ペプチドである、請求項1~8のいずれか1項記載の製剤。
- 自己抗原タンパク質が、疾患の増悪に寄与する抗原である、請求項9記載の製剤。
- 疾患が生活習慣病である、請求項10記載の製剤。
- 自己抗原タンパク質が、アンギオテンシンIIである、請求項10又は11記載の製剤。
- 心不全、高血圧症、腎不全、動脈硬化、心筋梗塞、脳梗塞、閉塞性動脈硬化症、又は認知症の治療又は予防用である、請求項12記載の製剤。
- 僧房弁閉鎖不全症に起因する心不全の治療又は予防用である、請求項13記載の製剤。
- 自己抗原タンパク質が、VEGFである、請求項10又は11記載の製剤。
- 癌、糖尿病性網膜症、加齢黄斑変性症、又は未熟児網膜症の治療又は予防用である、請求項15記載の製剤。
- 適用対象がヒトである、請求項1~16のいずれか1項記載の製剤。
- 適用対象が非ヒト哺乳動物である、請求項1~16のいずれか1項記載の製剤。
- 適用対象に対して、抗原性ペプチドに対する特異的免疫応答を誘導するための方法であって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を、実質的に同時に投与することを含む、方法。 - 抗原性ペプチドに対する特異的免疫応答の誘導において使用するための、組み合わせであって、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、組み合わせ。 - 抗原性ペプチドに対する特異的免疫応答を誘導するための医薬の製造における、組み合わせの使用であって、該組み合わせは、
(I) 当該抗原性ペプチド、及び
(II) 当該抗原性ペプチドが挿入又は付加されたキメラB型肝炎ウイルスコア抗原ポリペプチドをコードする発現ベクターであって、該抗原性ペプチドが、B型肝炎ウイルスコア抗原ポリペプチドのアミノ酸残基74~87又は130~138の領域内に挿入されているか、或いはB型肝炎ウイルスコア抗原ポリペプチドのN末端又はC末端に付加されている、発現ベクター
を含み、
(I)の抗原性ペプチドと、(II)の発現ベクターとが、適用対象に対して、実質的に同時に投与される、使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016560313A JP6706821B2 (ja) | 2014-11-20 | 2015-11-20 | Dna−ペプチド併用ワクチン |
CN201580073890.1A CN107530408A (zh) | 2014-11-20 | 2015-11-20 | Dna‑肽组合疫苗 |
US15/528,502 US10695420B2 (en) | 2014-11-20 | 2015-11-20 | DNA-peptide combination vaccine |
AU2015350904A AU2015350904A1 (en) | 2014-11-20 | 2015-11-20 | DNA-peptide combination vaccine |
EP15861370.3A EP3222289A4 (en) | 2014-11-20 | 2015-11-20 | Dna-peptide combination vaccine |
HK18104030.4A HK1244446A1 (zh) | 2014-11-20 | 2018-03-23 | Dna-肽組合疫苗 |
HK18108297.3A HK1248560A1 (zh) | 2014-11-20 | 2018-06-28 | Dna-肽組合疫苗 |
AU2021218181A AU2021218181A1 (en) | 2014-11-20 | 2021-08-20 | DNA-peptide combination vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-235736 | 2014-11-20 | ||
JP2014235736 | 2014-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016080540A1 true WO2016080540A1 (ja) | 2016-05-26 |
Family
ID=56014070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/082778 WO2016080540A1 (ja) | 2014-11-20 | 2015-11-20 | Dna-ペプチド併用ワクチン |
Country Status (7)
Country | Link |
---|---|
US (1) | US10695420B2 (ja) |
EP (1) | EP3222289A4 (ja) |
JP (1) | JP6706821B2 (ja) |
CN (1) | CN107530408A (ja) |
AU (2) | AU2015350904A1 (ja) |
HK (2) | HK1244446A1 (ja) |
WO (1) | WO2016080540A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
CN109663124B (zh) * | 2019-02-14 | 2022-05-13 | 武汉华纪元生物技术开发有限公司 | 针对人血管平滑肌细胞l型钙通道和血管紧张素1型受体的嵌合型二价降压疫苗及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03216186A (ja) * | 1989-09-19 | 1991-09-24 | Wellcome Found Ltd:The | キメラヘパドナウイルスコア抗原蛋白 |
WO2012141280A1 (ja) * | 2011-04-15 | 2012-10-18 | 国立大学法人 大阪大学 | Dnaワクチン |
WO2014034735A1 (ja) * | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
JP2014060968A (ja) * | 2012-09-21 | 2014-04-10 | Anges Mg Inc | アポリポプロテイン(a)の特異的エピトープを含むDNAワクチン |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307477A (ja) * | 2003-03-24 | 2004-11-04 | Kobe University | 遺伝子導入型ワクチンの中和抗体誘導能を増強する方法、ワクチンの投与方法 |
-
2015
- 2015-11-20 CN CN201580073890.1A patent/CN107530408A/zh active Pending
- 2015-11-20 US US15/528,502 patent/US10695420B2/en active Active
- 2015-11-20 EP EP15861370.3A patent/EP3222289A4/en active Pending
- 2015-11-20 AU AU2015350904A patent/AU2015350904A1/en not_active Abandoned
- 2015-11-20 WO PCT/JP2015/082778 patent/WO2016080540A1/ja active Application Filing
- 2015-11-20 JP JP2016560313A patent/JP6706821B2/ja active Active
-
2018
- 2018-03-23 HK HK18104030.4A patent/HK1244446A1/zh unknown
- 2018-06-28 HK HK18108297.3A patent/HK1248560A1/zh unknown
-
2021
- 2021-08-20 AU AU2021218181A patent/AU2021218181A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03216186A (ja) * | 1989-09-19 | 1991-09-24 | Wellcome Found Ltd:The | キメラヘパドナウイルスコア抗原蛋白 |
WO2012141280A1 (ja) * | 2011-04-15 | 2012-10-18 | 国立大学法人 大阪大学 | Dnaワクチン |
WO2014034735A1 (ja) * | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
JP2014060968A (ja) * | 2012-09-21 | 2014-04-10 | Anges Mg Inc | アポリポプロテイン(a)の特異的エピトープを含むDNAワクチン |
Non-Patent Citations (4)
Title |
---|
FELBER B.K. ET AL.: "HIV DNA Vaccine: Stepwise Improvements Make a Difference", VACCINES, vol. 2, May 2014 (2014-05-01), pages 354 - 379, XP055445564 * |
ISHIKAWA T. ET AL.: "Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice", MICROBES AND INFECTION, vol. 9, 2007, pages 1089 - 1095, XP022211644, DOI: doi:10.1016/j.micinf.2007.05.013 * |
See also references of EP3222289A4 * |
YANG Y. ET AL.: "Protective immune response induced by co-immunization with the Trichinella spiralis recombinant Ts87 protein and a Ts87 DNA vaccine", VETERINARY PARASITOLOGY, vol. 194, 2013, pages 207 - 210, XP028539095 * |
Also Published As
Publication number | Publication date |
---|---|
JP6706821B2 (ja) | 2020-06-10 |
AU2015350904A2 (en) | 2017-06-22 |
US20170258895A1 (en) | 2017-09-14 |
CN107530408A (zh) | 2018-01-02 |
EP3222289A4 (en) | 2018-07-04 |
HK1244446A1 (zh) | 2018-08-10 |
AU2021218181A1 (en) | 2021-09-09 |
EP3222289A1 (en) | 2017-09-27 |
US10695420B2 (en) | 2020-06-30 |
JPWO2016080540A1 (ja) | 2017-08-31 |
AU2015350904A1 (en) | 2017-06-15 |
HK1248560A1 (zh) | 2018-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102596236B (zh) | 抗原性Tau肽及其用途 | |
US9913886B2 (en) | DNA vaccine containing specific epitope of apolipoprotein (a) | |
KR102190180B1 (ko) | Dna 백신 | |
AU2020219804A1 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
AU2021218181A1 (en) | DNA-peptide combination vaccine | |
JP2023521722A (ja) | Apc標的化単位を用いたネオエピトープ免疫療法 | |
JP2018138573A (ja) | Vegf及び/又はアンギオポエチン−2の特異的エピトープを含むdnaワクチン | |
JP2005519033A (ja) | オステオポンチン関連組成物および方法 | |
JP2023507347A (ja) | ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15861370 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016560313 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15528502 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015861370 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015350904 Country of ref document: AU Date of ref document: 20151120 Kind code of ref document: A |